- Home
- PETS vs XTNT Comparison
PETS vs XTNT Comparison
Compare PETS & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- XTNT
- Stock Information
- Founded
- PETS 1996
- XTNT N/A
- Country
- PETS United States
- XTNT United States
- Employees
- PETS N/A
- XTNT N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- XTNT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PETS Consumer Staples
- XTNT Health Care
- Exchange
- PETS Nasdaq
- XTNT Nasdaq
- Market Cap
- PETS 62.8M
- XTNT 60.9M
- IPO Year
- PETS N/A
- XTNT N/A
- Fundamental
- Price
- PETS $3.74
- XTNT $0.67
- Analyst Decision
- PETS Sell
- XTNT
- Analyst Count
- PETS 2
- XTNT 0
- Target Price
- PETS $3.35
- XTNT N/A
- AVG Volume (30 Days)
- PETS 111.3K
- XTNT 440.0K
- Earning Date
- PETS 06-10-2025
- XTNT 05-12-2025
- Dividend Yield
- PETS N/A
- XTNT N/A
- EPS Growth
- PETS N/A
- XTNT N/A
- EPS
- PETS 0.02
- XTNT N/A
- Revenue
- PETS $247,010,000.00
- XTNT $122,298,000.00
- Revenue This Year
- PETS N/A
- XTNT $11.64
- Revenue Next Year
- PETS N/A
- XTNT $7.59
- P/E Ratio
- PETS $216.83
- XTNT N/A
- Revenue Growth
- PETS N/A
- XTNT 20.81
- 52 Week Low
- PETS $2.90
- XTNT $0.33
- 52 Week High
- PETS $6.85
- XTNT $0.83
- Technical
- Relative Strength Index (RSI)
- PETS 48.08
- XTNT 54.46
- Support Level
- PETS $3.56
- XTNT $0.64
- Resistance Level
- PETS $3.82
- XTNT $0.74
- Average True Range (ATR)
- PETS 0.18
- XTNT 0.06
- MACD
- PETS -0.01
- XTNT -0.00
- Stochastic Oscillator
- PETS 15.83
- XTNT 51.41
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About XTNT Xtant Medical Holdings Inc.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.